Phase
Condition
Neoplasms
Hematologic Neoplasms
Treatment
N/AClinical Study ID
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Karnofsky performance status ≥ 70
Presence of any kind of haematological malignancy in complete remission (CR1, CR2 oreCR3) at time of transplantation, with the exception of patients with myelodysplasticsyndrome.
Patients that are scheduled for a BMT either using stem cell derived from bone marrowor peripheral blood stem cells.
Candidates to receive a 10 Gy TBI treatment.
Ability to stay still and lying on the treatment couch for at least 45 minutes.
Informed Consent as documented by signature.
Exclusion
Exclusion Criteria:
Karnofsky performance status <70 intended as a patient unable to work; able to live athome and care for most personal needs with varying amount of assistance needed.
Concurrent treatment with other experimental drugs or other anti-cancer therapy.
Participation in another clinical trial and any concurrent treatment with anyinvestigational drug within 4 weeks prior to trial entry/randomisation.
Inability to comply with study and follow-up procedures.
Study Design
Study Description
Connect with a study center
University Hospital of Geneva
Genève, 1205
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.